1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Kadimastem Ltd

Kadimastem Ltd

KDST.TA
Kadimastem LtdIL flagTel Aviv Stock Exchange
2,794.00
ILA
- -
- -
125.73MMarket Cap
Kadimastem Ltd
KDST.TA
(Tel Aviv Stock Exchange)

Recent

price

2,794.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
1
1
2
2
4
4
4
Basic Weighted Avg Shares
- -
- -
1
2
1
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
1
1
1
1
1
- -
1
2
2
2
2
2
Depreciation Expense
-13
-15
-17
-20
-21
-24
-25
-22
-26
-23
-12
-27
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
2
- -
- -
2
1
- -
2
1
- -
LT Debt
- -
2
-1
-9
4
7
-12
-8
15
- -
-4
-29
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-109.14%
-258.11%
568.49%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
12.12%
13.6%
121.1%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
Tennor Therap-b (6872.HK)
Viridian Therapeutics, Inc. (0K1R.L)
3D Global Biotech Inc. (6808.TWO)
NanoLogix, Inc. (NNLX)
Alfavision Overseas (India) Limited (ALFAVIO.BO)
AdAlta Limited (1AD.AX)
Business
Kadimastem Ltd (TASE: KDST) is a clinical-stage biotechnology company that develops and manufactures off-the-shelf, allogeneic cell therapies derived from human embryonic stem cells for neurodegenerative diseases and diabetes; its lead product candidates include AstroRx, a clinical-grade astrocyte therapy administered intrathecally for amyotrophic lateral sclerosis and other neurodegenerative indications, and IsletRx, functional pancreatic islet cells producing insulin and glucagon for insulin-dependent diabetes. Founded in 2009 by Professor Michel Revel and headquartered at Pinchas Sapir Street, Weizmann Science Park, Nes Ziona, Israel, the company operates primarily in Israel with global development ambitions targeting patients with unmet needs in ALS and type 1 diabetes. In October 2025, Kadimastem merges with NLS Pharmaceutics Ltd to form NewcelX Ltd, headquartered in Zurich, Switzerland, and listed on Nasdaq under NCEL, combining cell therapy expertise with small molecule drug discovery to advance AstroRx into Phase IIa multi-site trials and IsletRx into Phase I; recent developments include a strategic collaboration with TargetGene for next-generation gene-edited cell therapies, continued BIRD Foundation support for the iTolerance diabetes program featuring IsletRx with microencapsulation, and up to $28 million in equity financing to bolster the merger and pipeline.